Company Metrics

• 0 P/E
• 16.84 P/S
• 10.32 P/B
• -0.03 EPS
• 552.60% Cash ROIC
• 3.13 Cash Ratio
• 0 / 0% Dividend
• 1.10M Avg. Vol.
• 104.27M Shares
• 344.1M Market Cap.

Company Description

Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. It offers injection devices, which include Medi-Jector Vision for insulin; Zomajet 2 Vision, Zomajet Vision X, Twin-Jector EZ II, and Tjet for human growth hormone; Vibex pressure assisted auto injector platform that enables a controlled pressure delivery of drugs into the body utilizing a spring power source; and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The company also develops/commercializes Anturol, an oxybutynin ATD (advanced transdermal delivery)gel, which is in Phase III clinical trials for the treatment of overactive bladder; Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; LibiGel, a transdermal testosterone gel that is in Phase III clinical studies for the treatment of female sexual dysfunction; Nestorone contraceptive formulation products, which has completed Phase II clinical trials; and Ropinerole to treat a central nervous system. Antares Pharma, Inc. markets its products to pharmaceutical companies primarily in the United States and Europe. It has collaborative arrangements and license agreements primarily with Teva Pharmaceutical Industries, Ltd.; BioSante Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Population Council, Ferring Pharmaceuticals BV; Eli Lilly and Company; JCR Pharmaceuticals Co., Ltd.; and Solvay Pharmaceuticals BV, as well as a strategic alliance with Uman Pharma. The company was formerly known as Medi-Ject Corporation and changed its name to Antares Pharma, Inc. in January 2001. Antares Pharma, Inc. was founded in 1979 and is based in Ewing, New Jersey.
less

Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. It offers injection devices, which include Medi-Jector Vision for insulin; Zomajet 2 Vision, Zomajet Vision X, Twin-Jector EZ II, and Tjet for human growth hormone; Vibex pressure assisted auto injector platform that enables a controlled pressure deliv...
more

News